KU LEUVEN

Rapid increase of vaccine serotype 4 (GPSC162) invasive pneumococcal disease in young adults since 2020 in Belgium

Cuypers Lize^{1,2}, Menten Bob¹, Sanchez Gerardo J², Laenen Lies^{1,2}, is **17-20 March 2024** Lagrou Katrien^{1,2}, Ombelet Sien^{1,2}, Desmet Stefanie^{1,2}



¹ University Hospitals Leuven, Department of Laboratory Medicine, National Reference Centre for Invasive Pneumococci, Leuven, Belgium ² KU Leuven, Department of Microbiology, Immunology and Transplantation, Laboratory of Clinical Microbiology, Leuven, Belgium

BACKGROUND	METHODS
 Following introduction of pneumococcal vaccination for children in Belgium in 2007: vaccine preventable serotype 4 IPD almost disappeared (<0.5% of all IPD cases) 	 Stable laboratory-based surveillance for IPD in Belgium: +/- 100 laboratories, spread even across the country, send isolates to the National Reference Center Capsular typing (Quellung reaction) for all IPD cases from 2007 to 2023 Serotype 4 strains from 2022 (n=102) were characterized by whole-genome sequencing: DNA extraction with DSP DNA Mini Kit QIAsymphony SP (Qiagen) Library preparation with Illumina DNA Prep Kit at the Nucleomics Core facility, KU Leuven


• Since 2020, resurgence of serotype 4

- Short-read sequencing with NextSeq2000 platform (PE250 600 cycli, Illumina)
- - 2022: 6.9% of all IPD cases
 - 2023: 9.6% of all IPD cases
- Downstream bioinformatics by Pathogenwatch to determine multi-locus sequence type (MLST) and Global Pneumococcal Sequence Cluster (GPSC)

RESULTS

Increasing number of serotype 4 cases since 2020

- Despite overall low numbers of IPD cases during the COVID-19 pandemic: important increase of serotype 4 infections since early 2020 (Figure 1)
- **Proportion of serotype 4 in time:**
 - PCV7 period: decrease from 55 cases in 2007 to 17 cases in 2011
 - PCV13 period 1: further decrease to 7 cases in 2015
 - PCV10 period: stable period ranging between 6 and 9 infections per year



- PCV13 period 2: increase from 6 to 167 cases, starting from 2020 on
- 2023: overall ranked third (9.6%)


Serotype 4 mainly in young male adults

- The increase of serotype 4 (2020-2023):
 - Mainly pronounced in males: 78.8% vs 55.5% for non-serotypes 4
 - Majority of infections in age category **18-64 years**: 75.6% (18-49y: 46.6%) and 50-64y: 29.1%)
 - Geography different compared to non-serotype 4 infections:
 - More frequent in Brussels-Capital region (32.2% vs 9.9%)
 - Less frequent in Flanders (northern part) (28.1% vs 60.2%)
 - Enriched in large cities (not shown in Figure 2)

Dominance of sequence types 801 and 15063 (93.2%)

Year

Figure 1: Number of IPD isolates between 2007 and 2023: serotype 4 (blue line) and non-serotype 4 infections (grey bars). The period of the COVID-19 pandemic is indicated by an orange bar. The number of IPD cases of serotype 4 is indicated for each year.



- Sequencing of 102 serotype 4 strains (2022) identified **six ST types**:
 - ST801: 71.6% (GPSC162)
 - ST15063: 21.6% (GPSC162)
 - Rare STs: 205 (3.9%) 1022, 5838 and 13753 (each <1.0%)
 - Geographical differences for the major STs (Figure 2)

Figure 2: Number of IPD serotype 4 isolates mapped per Belgian province for the year 2022 (n=102). Sequence types are visualized for the provinces with 10 or more isolates.

CONTACT

lize.cuypers@uzleuven.be

LT-20 March 2024 SPPD-13 Cape Town South Africa

Abstract #368

CONCLUSION

The continued increase of serotype 4 IPD since early 2020 is due to an increase in infections in younger adults (18-49 years), mainly males and living in specific regions in the country. Two clones (ST801 and 15063: 93.2%) are responsible for this worrisome increase of a vaccine serotype in an age group currently not targeted for vaccination, accounting for 1 in 4 infections for the young adults in 2023. Further characterization of the serotype 4 cases and genomic comparisons are ongoing to better understand this evolution.